Seres Therapeutics Inc. (MCRB) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Seres Therapeutics Inc. (MCRB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.77

0.00 (0.48%)

At close: Jan 15, 2025, 12:45 PM

undefined% (undefined)

Bid	0.77
Market Cap	132.30M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.4
PE Ratio (ttm)	-1.94
Forward PE	n/a
Analyst	Buy

Ask	0.78
Volume	630,973
Avg. Volume (20D)	2,515,555
Open	0.78
Previous Close	0.77
Day's Range	0.75 - 0.81
52-Week Range	0.54 - 1.53
Beta	undefined

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteri...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 26, 2015

Employees 233

Stock Exchange NASDAQ

Ticker Symbol MCRB

Website https://www.serestherapeutics.com

Analyst Forecast

According to 4 analyst ratings, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is $5.62, which is an increase of 625.25% from the latest price.

Buy 50.00%

Hold 25.00%

Sell 25.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

+3.86%

Seres Therapeutics shares are trading higher after... Unlock content with Pro Subscription

3 months ago · Source

+10.44%

Seres Therapeutics shares are trading higher after the company announced its stockholders voted to approve the previously announced proposed sale of its VOWST business to Société des Produits Nestlé S.A.

News

2 months ago · seekingalpha.com

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - Chief Executive Officer Lisa vo...